Skip to main content
FutureChem Co., Ltd. logo

FutureChem Co., Ltd. — Investor Relations & Filings

Ticker · 220100 ISIN · KR7220100002 KO Manufacturing
Open in API
Filings indexed 312 across all filing types
Latest filing 2022-03-11 AGM Information
Country KR South Korea
Listing KO 220100

About FutureChem Co., Ltd.

https://www.futurechem.co.kr/?language=…

FutureChem Co., Ltd. is a company specializing in the development and production of radiopharmaceuticals for diagnostic and therapeutic applications. The company's operations cover the manufacturing of radiopharmaceutical precursors, chemical compounds, synthesis reagents, and automated synthesis modules. Its product pipeline focuses on agents for the diagnosis and treatment of various cancers and neurological disorders, including Parkinson's disease. FutureChem supports the broader radiopharmaceutical field by providing both finished products and the essential chemical building blocks and equipment required for their synthesis. The company actively establishes global partnerships for clinical supply and commercial licensing of its technologies.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company FutureChem. It outlines the date, location, agenda items (such as financial statement approval, director appointments, and remuneration limits), and details regarding the board of directors. This type of document is a standard proxy solicitation or notice of meeting material provided to shareholders to inform them of upcoming voting matters.
2022-03-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for FutureChem. It contains the meeting date, location, agenda items (financial statement approval, director appointments, remuneration limits), and information regarding electronic voting and proxy solicitation. This document is a formal notice sent to shareholders to inform them of an upcoming meeting and to solicit their votes, which fits the definition of a Proxy Solicitation & Information Statement.
2022-03-11 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy/Voting Rights) issued by FutureChem. It contains detailed information regarding the upcoming Annual General Meeting (AGM), including the agenda, voting procedures (electronic/proxy), and the company's financial statements and business status to inform shareholders for their vote. This document is a standard proxy solicitation statement used to request shareholder votes for an AGM.
2022-03-11 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (FutureChem) announcing a significant change in financial results (revenue or profit/loss structure exceeding 15% or 30%). This is a standard regulatory disclosure requirement in the Korean market (DART system) for reporting preliminary financial performance before the final audit report is finalized. Since it is an initial announcement of financial results rather than a full annual report or a simple report publication notice, it falls under the Earnings Release (ER) category. FY 2021
2022-02-11 Korean
투자판단관련주요경영사항(전이성 거세저항성 전립선암 환자에 대한 [177Lu]루도타다이펩의 반복투여 치료의 안전성 및 유효성 평가; 제2상 임상시험계획 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically details the application for a Phase 2 clinical trial for a new drug candidate ([177Lu]Ludotadipep). Since this is a formal regulatory disclosure of a material business event (clinical trial application) that does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2022-02-08 Korean
투자판단관련주요경영사항(생화학적 재발 전립선암(BRPC) 환자에서의 [18F]Florastamin PET/CT 영상검사의 진단 유효성 및 안전성을 평가하기 위한 다기관, 단일군, 공개, 제3상 임상시험 IND 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) system, specifically a 'Major Management Disclosure' (투자판단 관련 주요경영사항). It details the submission of an Investigational New Drug (IND) application for a Phase 3 clinical trial. Since this is a specific regulatory announcement regarding company operations and clinical trial status that does not fit into categories like financial reports, dividends, or shareholder meetings, it falls under the 'Regulatory Filings' (RNS) category.
2022-02-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.